OTCPK:SCAL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Stem Cell Authority's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SCAL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

SCAL

-1.5%

US Healthcare

-3.1%

US Market


1 Year Return

239,900.0%

SCAL

16.7%

US Healthcare

12.7%

US Market

Return vs Industry: SCAL exceeded the US Healthcare industry which returned 17.8% over the past year.

Return vs Market: SCAL exceeded the US Market which returned 12.9% over the past year.


Shareholder returns

SCALIndustryMarket
7 Day0%-1.5%-3.1%
30 Day0%-5.4%-2.9%
90 Dayn/a1.5%8.2%
1 Year239,900.0%239,900.0%18.3%16.7%15.3%12.7%
3 Yearn/a26.0%20.5%37.8%28.5%
5 Year23,900.0%23,900.0%55.9%44.9%90.9%69.4%

Price Volatility Vs. Market

How volatile is Stem Cell Authority's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Stem Cell Authority undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Stem Cell Authority is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Stem Cell Authority has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Examine Stem Cell Authority's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Stem Cell Authority regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Stem Cell Authority forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

13.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Stem Cell Authority has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Stem Cell Authority performed over the past 5 years?

7.7%

Historical Healthcare annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Stem Cell Authority has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Stem Cell Authority's financial position?


In this section we usually analyse Stem Cell Authority's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Stem Cell Authority has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of SCAL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Stem Cell Authority's financial data was last updated here.
  • Explore more healthy companies in the Healthcare industry.

Dividend

What is Stem Cell Authority current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SCAL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SCAL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SCAL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCAL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCAL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Carlzo Cardwell

no data

Tenure

Mr. Carlzo Bernard Cardwell is the Founder, Chief Executive Officer and President of Stem Cell Authority, Ltd. (Formerly Five Nines Ltd) and served as its Chairman and Director since May 2005. Mr. Cardwell ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Stem Cell Authority, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stem Cell Authority, Ltd.
  • Ticker: SCAL
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$842.042k
  • Shares outstanding: 350.85m
  • Website: https://www.stemcellauthority.com

Location

  • Stem Cell Authority, Ltd.
  • 123 South Miller Road
  • Fairlawn
  • Ohio
  • 44333
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCALOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2005

Biography

Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells. It specializes in the collection and cryogenic preservation of the hematopoi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/22 05:58
End of Day Share Price2020/09/15 00:00
Earnings2009/08/31
Annual Earnings2009/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.